Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010
Open Access
- 15 October 2015
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 4 (1) , 612
Abstract
Monitoring the use of antibiotics is relevant due to the public health impact of microbial resistance, adverse effects, and costs. We present data on the consumption of macrolides, lincosamides, streptogramins and amoxicillin/clavulanate (AMC) between 2007 and 2010 in the in-and outpatient healthcare setting in 10 European countries provided by IMS Health. Antibiotics were classified according to the anatomical therapeutic chemical classification and consumption was expressed in defined daily doses/1000 inhabitants/day (DIDs). We analysed the number of prescriptions by diagnostic codes between 2008 and 2010, based on the International Classification of Diseases, 10th revision (ICD-10). These ICD-10 codes were grouped into four main categories: respiratory infections, genitourinary infections, other infections and other diagnoses. In 2010, the consumption of macrolides and lincosamides ranged from 0.45 DIDs (Sweden) to 5.46 DIDs (Italy), and from 0.04 DIDs (Denmark) to 1.00 DID (Germany), respectively. Streptogramins were available in France, Germany, Italy, Norway, Spain and United Kingdom with a consumption of <0.001 DID exclusively in the hospital setting. The consumption of AMC ranged from <0.001 DIDs (Norway) to 11.67 DIDs (Spain). During the study period, the consumption of macrolides decreased, the consumption of AMC increased in most of European countries, and lincosamides varied very slightly. Macrolides and AMC were mainly prescribed for respiratory infections in all countries but United Kingdom, where most of the prescriptions were assigned to diagnostic codes not clearly related with an infection. Lincosamides were prescribed for the respiratory infections and other infections groups. There was a wide inter-country variability in the percentage of the prescriptions assigned to each of the diagnostic categories. The inter-country differences in the consumption of these antibiotics and their prescription by diagnostic categories point to an inappropriate use of antibiotics.Keywords
This publication has 16 references indexed in Scilit:
- Bridging Differences in Outcomes of Pharmacoepidemiological Studies: Design and First Results of the PROTECT ProjectCurrent Clinical Pharmacology, 2014
- Antibiotic use in Dutch primary care: relation between diagnosis, consultation and treatmentJournal of Antimicrobial Chemotherapy, 2014
- Determinants of between-country differences in ambulatory antibiotic use and antibiotic resistance in Europe: a longitudinal observational studyJournal of Antimicrobial Chemotherapy, 2013
- European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in EuropeJournal of Antimicrobial Chemotherapy, 2009
- Antibiotic prescribing over the last 16 years: fewer antibiotics but the spectrum is broadeningEuropean Journal of Clinical Microbiology & Infectious Diseases, 2009
- Are cultural dimensions relevant for explaining cross-national differences in antibiotic use in Europe?BMC Health Services Research, 2008
- Antibacterial prescribing in primary careJournal of Antimicrobial Chemotherapy, 2007
- Antibiotic use in ambulatory care in Europe (ESAC data 1997–2002): trends, regional differences and seasonal fluctuationsPharmacoepidemiology and Drug Safety, 2006
- Differences in antibiotic prescribing among physicians, residents, and nonphysician cliniciansThe American Journal of Medicine, 2005
- European Surveillance of Antimicrobial Consumption (ESAC): Data Collection Performance and Methodological ApproachBritish Journal of Clinical Pharmacology, 2004